checkAd
    Startseite > Aktien > Foghorn Therapeutics > Nachrichten
    Foghorn Therapeutics Aktie
    5,2900
     
    USD
    -6,70 %
    -0,3800 USD
    Letzter Kurs 02:00:00 Nasdaq
    5,2900
     
    USD
    200 STK
    Geldkurs 15.05.24
    5,3900
     
    USD
    100 STK
    Briefkurs 15.05.24
    ISIN: US3441741077 · WKN: A2QFQD · SYM: FHTX · USA

    Neueste Nachrichten

    Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
    06.05.24 · globenewswire · Foghorn Therapeutics
    Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
    16.04.24 · globenewswire · Foghorn Therapeutics
    Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
    09.04.24 · globenewswire · Foghorn Therapeutics
    Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
    05.04.24 · globenewswire · Foghorn Therapeutics
    Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
    26.03.24 · globenewswire · Foghorn Therapeutics
    Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
    07.03.24 · globenewswire · Foghorn Therapeutics
    Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909
    05.03.24 · globenewswire · Foghorn Therapeutics
    Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
    05.03.24 · globenewswire · Foghorn Therapeutics
    Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
    28.02.24 · globenewswire · Foghorn Therapeutics
    Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
    08.02.24 · globenewswire · Foghorn Therapeutics
    Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
    08.01.24 · globenewswire · Foghorn Therapeutics
    Foghorn Therapeutics Announces CFO Departure
    03.01.24 · globenewswire · Foghorn Therapeutics